Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance.

Type 2 diabetes has high long-team health and resource impact, as a result of its vascular complications and needed therapies. Prevention of diabetes then seems to be attractive. Previous studies have identifi ed that lifestyle interventions and some therapeutic approaches can prevent or delay the onset of diabetes in those with hyperglycaemia. Such… CONTINUE READING